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ABSTRACT 
A sensitive and high throughput ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method has 
been developed for the determination of sirolimus in human whole blood. The method involved protein precipitation with ZnSO4, 
followed by solid phase extraction of sirolimus along with tacrolimus as the internal standard (IS) from 100 µL of human blood. The 
chromatographic analysis was achieved on a Waters Acquity UPLC BEH C18 (50 mm × 2.1 mm, 1.7 µm) analytical column using 
gradient mobile phase, consisting of 10 mM ammonium acetate, pH 5.00 adjusted with acetic acid and premixed methanol and 
acetonitrile (60:40, v/v), at a flow-rate of 0.400 mL/min. The precursor → product ion transition for sirolimus (m/z 931.6 → 864.4), and 
IS (m/z 821.5 → 768.3) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring and 
positive ionization mode. The method is validated over a wide dynamic concentration range of 0.05-50.0 ng/mL. Matrix effect is 
assessed by post-column analyte infusion experiment and the mean extraction recovery was greater than 93.0 % for sirolimus and IS. 
The method is rugged and rapid with a total run time of 1.5 min and was used in a clinical study with 16 healthy subjects. The assay 
reproducibility was successfully demonstrated by reanalysis of 87 subject samples.   
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INTRODUCTION
Sirolimus (rapamycin), a macrocyclic fermentation 
product isolated from Streptomyces hygroscopicus is a potent 
non-calcineurin inhibiting immunosuppressant. It is generally 
used in combination with calcineurin inhibitors like tacrolimus 
and cyclosporine A or mycophenolate mofetil for the prophylaxis 
of organ rejection in organ transplant patients [1-3]. It possesses 
both immunosuppressants as well as antiproliferative properties, 
and has a unique mechanism of action which is different from the 
calcineurin inhibitors. Sirolimus was approved in the US in 1999 
and in Canada and Europe in 2001 for the prevention of renal 
transplant rejection [2]. Although sirolimus and tacrolimus have 
structural similarity, their mechanism of action is quite different. 
Like tacrolimus, sirolimus binds with FKBP12 however; the 
sirolimus-FKBP12 complex has no effect on calcineurin 
phosphatase unlike tacrolimus. Instead it binds with one or more 
proteins known as mammalian targets of rapamycin (mTOR) and 
thus inhibits both DNA and protein synthesis, resulting in 
obstruction of the cell cycle in late G1 phase as it progresses to the 
S phase [4, 5]. Thus, sirolimus reduces T-cell activation at a later 
stage in the cell cycle than the calcineurin inhibitors by inhibiting 
cytokine-induced signal transduction pathways, resulting in the 
suppression of interleukin (IL)-2- and IL-4-driven T-cell 
proliferation [6].  
Sirolimus is essentially distributed in the erythrocytes (~ 
95 %), which is not temperature or concentration dependent. The 
sequestration of sirolimus in the red blood cells is due to their rich 
content of immunophilins. Sirolimus displays concentration 
dependent binding to lipoproteins (about 40 %), while in the 
remaining 60 % unbound fraction only 4 % is bound to plasma 
proteins. Therefore, whole blood is the preferred matrix for 
therapeutic drug monitoring. Sirolimus is mainly metabolized by 
the CYP-450 enzyme system to give several metabolites, mainly 
hydroxyl-, demethyl-, di-demethyl- and dihydroxy-sirolimus. 
However, the metabolites show less than 10 % of the parent 
compounds activity and their elimination is through faecal 
pathway. Further, sirolimus has a long elimination half-life of 
approximately 62 h [7, 8]. 
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All the immunosuppressant drugs are characterized by a 
narrow therapeutic range and thus presence of elevated 
concentration can result in severe toxicity and under dosing can 
render them ineffective. Due to the narrow therapeutic indices, 
lack of a reliable correlation between dose and drug exposure, 
variable pharmacokinetics, and potential drug–drug interactions, 
several reports have recommended therapeutic drug monitoring 
(TDM) for sirolimus, both to prevent side effects (mainly 
thrombocytopenia and hypercholesterolemia) and to optimize 
efficacy and reduce organ rejection [9]. 
Literature presents two approaches for the estimation of 
sirolimus concentration in whole blood, namely immunoassays 
[10-13] and liquid chromatographic methods with UV [14-18] or 
mass spectrometric detection [9, 19-41]. Although immunoassays 
are highly selective, cross-reactivity of the drug with some 
metabolites results in overestimation of the concentrations and 
thus is a major problem with such methods. Amongst the 
chromatographic methods, sirolimus has been determined either 
as a single analyte [9, 14-17, 19-22] or in combination with other 
immunosuppressants [18, 23-41]. So far only two methods based 
on UPLC-MS/MS have been reported for sirolimus together with 
three other immunosuppressants [42, 43]. The sensitivity achieved 
was 1.0 ng/mL for sirolimus in both the methods. 
In the present work an accurate, highly sensitive and rapid 
UPLC-MS/MS method has been developed and fully validated for 
reliable measurement of sirolimus in human blood samples 
especially for routine therapeutic drug monitoring. The method 
requires only 100 µL human blood sample for extraction and 
demonstrates excellent performance in terms of ruggedness and 
efficiency (1.5 min per sample). Interference due to matrix was 
ascertained by post column infusion technique. It was successfully 
applied to a bioequivalence study in 16 healthy human subjects.  
 
EXPERIMENTAL 
Chemicals and materials 
Reference standards of sirolimus (99.6%) and tacrolimus 
(IS, 98.5%) were obtained from Toronto Research Chemicals 
(Toronto, Canada). HPLC grade acetonitrile and methanol were 
procured from Merck (Darmstadt, Germany). Acetic acid and zinc 
sulfate were purchased from Spectrochem Pvt. Ltd. (Mumbai, 
India) and SD Fine Chem. Ltd (Mumbai, India) respectively. 
Ammonium acetate was purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Water used in the entire analysis was prepared 
from Milli-Q water purification system from Millipore 
(Bangalore, India). Lichrosep Sequence SPE Cartridge (30 mg, 1 
mL) was purchased from Merck. Blank human blood was 
obtained from in-house clinical department and was stored at –20 
°C until use. 
Liquid chromatographic and mass spectrometric conditions 
A Waters Acquity UPLC system (MA, USA) consisting of 
binary solvent manager, sample manager and column manager 
was used for setting the reverse-phase liquid chromatographic 
conditions. The analysis of sirolimus and IS was performed on an 
analytical column maintained at 40°C in a column oven. For 
gradient elution, the mobile phase solvent consisted of (A) 10mM 
ammonium acetate, pH 5.00 adjusted with acetic acid and (B) 
premixed methanol and acetonitrile (60:40, v/v). A binary step 
gradient at a flow rate of 0.400 mL/min was employed. Up to 0.5 
min, the ratio of A and B was kept at 98:2 (v/v) and from 0.5 min 
to 1.0 min the ratio was switched to 2:98 (v/v), before returning to 
the starting conditions [A:B, 98:2 (v/v)] up to 1.5 min. 
Ionization and detection of sirolimus and IS was carried 
out on a triple quadrupole mass spectrometer from Waters – Micro 
Mass Technologies (MA, USA), equipped with turbo ion spray 
interface and operating in positive ionization mode. Quantitation 
was performed using multiple reaction monitoring (MRM) mode 
to monitor precursor → product ion transitions of m/z 931.6 → 
864.4 for sirolimus and m/z 821.5 → 768.3 for IS. A qualifying 
transition of m/z 931.6 → 896.4 and m/z 821.5 → 786.7 was also 
measured for the analyte and IS respectively. For both the 
compounds, the optimized mass spectrometer parameters were as 
follows, capillary voltage 3.0 kV, desolvation temperature 300 oC, 
desolvation gas flow 700 L/h, cone gas flow 100 L/h, and source 
temperature 100 oC. The compound specific parameters like cone 
voltage and collision energy were set at 30 V and 19 eV for 
sirolimus and 28 V and 21 eV for IS respectively. Quadrupole 1 
and 3 were maintained at unit mass resolution and the dwell time 
was set at 100 ms for both the drugs. Data collection, peak 
integration, and calculations were performed using Mass Lynx 
software version 4.1.  
Standard stock, calibration standards and quality control 
samples  
The standard stock solution of sirolimus (1000 µg/mL) was 
prepared by dissolving requisite amount in methanol. Calibration 
standards (CSs) and quality control (QC) samples were prepared 
by spiking (2% of total blood volume) blank blood with stock 
solution. Calibration curve standards were made at 0.050, 0.100, 
0.300, 1.20, 4.00, 10.0, 25.0, 40.0, and 50.0 ng/mL concentrations 
respectively, while quality control samples were prepared at three 
levels, viz. 45.0 ng/mL (HQC, high quality control), 25.0/2.50 
ng/mL (MQC-1/2, middle quality control 1/2), and 0.150 ng/mL 
(LQC, low quality control). Stock solution (0.2 mg/mL) of the 
internal standard was prepared by dissolving 5.0 mg of in 25.0 mL 
of methanol. Its working solution (100ng/mL) was prepared by 
appropriate dilution of the stock solution in methanol. Standard 
stock and working solutions used were stored at 5 °C, while CSs 
and QC samples in plasma were kept at -70 °C until use. 
Sample extraction protocol 
Prior to analysis, all frozen subject samples, calibration standards 
and quality control samples were thawed and allowed to 
equilibrate at room temperature. To an aliquot of 100 µL of spiked 
blood sample, 25 µL of internal standard was added and 
vortex-mixed for about 10 sec. Further, the mixture was pretreated 
with 500 µL of 0.1M zinc sulphate solution in water to lyse the 
cells, followed by vortex-mixing for 1.0 min. Following 
centrifugation at 1811 × g for 2 min, the supernatant was separated 
and applied to solid phase extraction (SPE) on a Lichrosep 
Sequence SPE cartridge which was previously conditioned with 
1.0 mL of methanol followed by 1.0 mL of water. The cartridge 
was first washed with 1.0 mL 10% acetic acid in water and then 
with 1.0 mL, 10 % methanol in water. Elution was carried with 
500 µL methanol in pre-labeled RIA vials. The solvent was then 
evaporated to dryness in a thermostatically controlled water bath 
maintained at 40 °C under a gentle stream of nitrogen. The dried 
sample was reconstituted in 100 µL of the mobile phase and 10 µL 
was used for injection into the chromatographic system. 
Method validation procedures 
The validation protocol and the acceptance criterion were 
essentially based on the USFDA guidelines [44].  
System suitability was checked by injecting 6 successive 
injections of aqueous samples of sirolimus (25 ng/mL) and IS (100 
ng/mL) at the beginning of each batch. The precision (%CV) in 
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the measurement of retention time it was in the range of 0.08-0.17 
%, and 1.15 to 2.12 for area response of sirolimus and IS. The 
system performance was also verified with one processed blank 
sample, one upper limit of quantitation and one LLOQ along with 
the IS at the beginning and end of each batch. The S/N ratio was ≥ 
70 for the analyte and IS. The auto sampler carry over for the 
analyte was checked by injecting the following sequence of 
injections: processed blank plasma, upper limit of quantitation 
(ULOQ) sample, processed blank plasma,  LLOQ sample, and 
processed blank plasma.  
The selectivity of the method was checked in eight 
different batches/lots of blank blood. The method linearity was 
evaluated from five linearity curves using least square weighted 
(1/x2) linear regression. Intra-batch accuracy and precision was 
assessed by analyzing six replicates of LQC, MQC-1/2, and HQC 
samples from a single batch on the same day, while for 
inter-batch, five batches were analyzed on three consecutive days 
in a similar manner.  
Ion suppression/enhancement effects on the method 
sensitivity and selectivity was studied by the post column analyte 
infusion experiment. A standard solution containing sirolimus (25 
ng/mL) and IS (100 ng/mL) was infused post column via a ‘T’ 
connector into the mobile phase at 10µL/min employing an 
in-built infusion pump. Further, 10 µL aliquots of extracted 
control blood were then injected into the column and 
chromatogram was acquired for sirolimus and IS.  
The extraction recovery and matrix effect were determined 
at four QC levels in six replicates as reported previously [45]. 
Relative recovery or extraction recovery was calculated by 
comparing the mean area response of extracted samples (spiked 
before extraction) to that of unextracted samples (spiked after 
extraction) at each QC level for the analyte and IS. Absolute 
matrix effect was computed by comparing the mean area response 
of unextracted samples (spiked after extraction) with mean area of 
neat standard solutions. Further, the effect of blood matrix on the 
analyte quantification, expressed as relative matrix effect was also 
checked in eight different batches/lots of blood. The assessment of 
relative matrix effect was based on the calculation of precision (% 
CV) values for slopes of calibration lines prepared from these 
batches. For a method to be practically free from relative matrix 
effect the % CV should not exceed 3-4 %.  
The stability of sirolimus and IS was examined in stock 
solutions and for the analyte in matrix by comparing the area 
response ratio (sirolimus/IS) of the stability samples with freshly 
prepared comparison samples.  Bench top stability at room 
temperature, wet extract (autosampler) stability at 5 °C, 
freeze-thaw and long-term stability (at -20°C and -70°C) in spiked 
blood samples were determined at LQC and HQC levels in six 
replicates.  
Dilution reliability was established from six replicates of 
standards prepared at 1/2 (45.0 ng/mL) and 1/10th (9.00 ng/mL) 
dilution, by spiking standard stock solution of sirolimus having 
90.0 ng/mL concentration in screened blank blood. The precision 
and accuracy were evaluated by comparing the results against 
freshly prepared calibration curve standards. Method ruggedness 
was ascertained by analyzing two precision and accuracy batches. 
The first batch was analyzed by different analysts while the 
second batch was studied on two different columns.  
Application of the method  
The method was applied for a clinical study in 16 healthy Indian 
subjects under fasting conditions. The design of the study was an 
open label, balanced, randomized, single dose, two treatment, two 
sequence, two period, crossover bioequivalence of a test (2.0 mg 
sirolimus tablets from an Indian Pharmaceuticals Company, India) 
and reference (2.0 mg sirolimus tablets, Rapamune from Wyeth 
Pharmaceuticals Inc., subsidiary of Pfizer Inc., Philadelphia, 
USA) formulation. The study was performed as per the 
International Conference on Harmonization and USFDA 
guidelines [46]. An Independent Ethics Committee approved the 
study protocol and a written consent was provided by all the 
subjects before enrolment in the study. Blood samples for the 
determination of sirolimus were collected in K3EDTA-vacuettes 
at pre-dose (0.00), 0.50, 1.00, 1.50, 2.00, 2.33, 2.67, 3.00, 3.33, 
3.67, 4.00, 4.33, 4.67, 5.00, 5.33, 5.67, 6.00, 6.33, 6.67, 7.00, 8.00, 
10.0, 12.0, 24.0, 36.0, 48.0, and 72.0 h after oral administration of 
the drug.  The samples were divided into two aliquots and stored 
in two different pre-labeled RIA vials at –70 °C until analysis. The 
pharmacokinetic parameters of sirolimus were estimated by 
non-compartmental model using WinNonlin software version 
5.2.1 (Pharsight Corporation, Sunnyvale, CA, USA). The Cmax 
values and the time to reach maximum blood concentration (Tmax) 
were estimated directly from the observed blood concentration vs. 
time data. The area under the blood concentration–time curve 
from time 0 to 72 h (AUC0-72) was calculated using the linear 
trapezoidal rule. To determine whether the test and reference 
formulations were pharmacokinetically equivalent, Cmax, and 
AUC0-72 and their ratios (test/reference) using log transformed 
data were assessed; their means and 90% CIs were analyzed by 
using SAS® software version 9.1.3 (SAS Institute Inc., Cary, NC, 
USA). The drugs were considered pharmacokinetically equivalent 
if the difference between the compared parameters was 
statistically non-significant (P ≥ 0.05) and the 90% confidence 
intervals (CI) for these parameters fell within 80 to 125%. 
The assay reproducibility was confirmed by reanalysis of 
87 subject sample (10 % of total subject samples analyzed). The 
selection criteria included samples which were near the Cmax and 
the elimination phase in the pharmacokinetic profile of sirolimus. 
The results obtained were compared with the initial values. The 
percent change in the value should not be more than ±20% [47]. 
 
RESULTS AND DISCUSSION  
Method development 
To achieve the desired sensitivity and selectivity, the 
extraction procedure, chromatography and mass detection 
parameters were suitably optimized. In the present work, 
electrospray ionization (ESI) source was used to maximize 
sensitivity and obtain good linearity in the regression curves. As 
observed in several reports [30, 35, 41 and 48] sirolimus has low 
affinity for protons and therefore the protonated precursor ions in 
the positive ionization mode have very low abundance and thus 
remain undetected. The Q1 scan for sirolimus and IS showed 
strong ability to bind with ammonium ions (from ammonium 
acetate used in the mobile phase) to give peaks at m/z 931.6 and 
821.5 corresponding to ammonium ion adducts with much higher 
abundance. These adducts can be readily fragmented to give stable 
and consistent product ions. The most abundant product ions 
obtained from the ammonium ion adducts in the Q3 scan 
corresponded to m/z 864.4 (neutral loss of H2O, NH3 and CH3OH) 
and 768.3 (neutral loss of 2H2O and NH3) for sirolimus and IS 
respectively (Figure 1). In addition to the quantification 
transition, a qualifying transition was also monitored for the 
identification of the analyte (m/z 931.6 → 896.4) and IS (m/z 
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821.5 → 786.7). A dwell time of 100 ms for sirolimus and IS was 
adequate to have sufficient no. of data points for quantification.   
 
 
Figure 1 Product ion mass spectra of (A) sirolimus (m/z 931.6 → 
864.4, scan range 50-1000 amu) and (B) tacrolimus ( IS, m/z 
821.5 →  768.3, scan range 50-1000 amu) in the positive 
ionization mode. 
 
Several chromatographic methods have been reported for 
the analysis of sirolimus from whole blood using isocratic [17] as 
well as gradient conditions [27, 28, 35]. Initially, chromatography 
under isocratic conditions was tried using various combinations of 
acetonitrile/methanol-aqueous component with acidic and 
alkaline buffers (formic acid/acetic acid-ammonium formate/ 
ammonium acetate, ammonia-ammonium formate) to achieve 
good resolution and symmetric peak shapes as well as to have 
shorter run time on Acquity UPLC BEH C18 (50 mm × 2.1mm, 
1.7µm) column. It was possible to have adequate retention, 
acceptable capacity factor and relatively good peak shape for 
sirolimus. Nevertheless, it was difficult to achieve the desired 
sensitivity of 0.05 ng/mL. Thus gradient conditions were tested 
and the best performance in terms of sensitivity, peak shape and 
short analysis time was possible using a binary step gradient with 
solvent A consisting of 10mM ammonium acetate, pH 5.00 
adjusted with acetic acid and solvent B having premixed methanol 
and acetonitrile (60:40, v/v), by maintaining a flow rate of 0.400 
mL/min. Initially up to 0.5 min, the ratio of A and B was kept at 
98:2 (v/v) and from 0.5 min to 1.0 min the ratio was switched to 
2:98 (v/v), before returning to the starting conditions [A:B, 98:2 
(v/v)] up to 1.5 min. This ensured a retention time of 1.01 and 0.95 
for sirolimus and IS respectively. Tacrolimus which is also an 
immunosuppressant drug was efficiently used as an internal 
standard in the present study. It had similar chromatographic 
elution pattern and did not affect the overall accuracy and 
precision of the method. The MRM ion chromatograms in Figure 
2 of extracted blank blood (double blank), blank blood fortified 
with IS, sirolimus at (0.05 ng/mL) and IS and a subject sample at 
Cmax demonstrates the selectivity of the method.  
Sample preparation is a decisive step for precise and 
accurate quantitation by LC-MS/MS methods. Majority of the 
methods available in literature have demonstrated a combination 
of protein precipitation followed by SPE for precise and 
quantitative recovery of sirolimus from whole blood [22, 42]. As 
sirolimus is sequestered within the erythrocytes, it is essential to 
break the binding with RBCs. Thus, a protein precipitant is 
required to lyse the cells and free the analyte. ZnSO4 was used as 
protein precipitant as reported by several authors [17, 22, 27, 42], 
followed by SPE on LiChrosep Sequence extraction cartridges 
employing 100 µL blood samples. Washing of cartridges with 1.0 
mL 10% acetic acid in water followed by 1.0 mL, 10 % methanol 
in water was adequate to remove endogenous compounds. The 
recovery of sirolimus was quantitative using 500 µL methanol for 
elution at all QC levels. 
 
 
Figure 2 MRM ion-chromatograms of (A) double blank blood 
(without IS) (B) blank blood with tacrolimus (IS, m/z 821.5 → 
768.3), (C) sirolimus (m/z 931.6 → 864.4) at LLOQ and IS (D) 
subject  sample at Cmax after administration of 2.0 mg dose of 
sirolimus.  
Results of post-column infusion experiment in Figure 3 indicate 
no ion suppression or enhancement at the retention time of 
sirolimus and IS. Though major ion suppression was observed 
around 0.5 min, however, it did not affect in the quantitation of 
sirolimus. 
I. Assay validation results 
 Carryover evaluation was performed in each analytical run 
so as to ensure that it does not affect the accuracy and the precision 
of the proposed method. Practically, there was no carry-over 
observed during autosampler carryover experiment. No 
enhancement in the response was observed in double blank after 
subsequent injection of highest calibration standard (aqueous and 
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extracted) at the retention time of sirolimus and IS respectively as 
shown in Figure 4.  
The calibration curves were linear over the concentration 
range of 0.050–50.0ng/mL. A straight-line fit was made through 
the data points by least square regression analysis and a constant 
proportionality was observed. The mean and standard deviation 
value for slope, intercept and correlation coefficient (r2) observed 
were 0.0331280 and 0.001445; 0.0013210 and 0.000489; 
0.9991237 and 0.000486 respectively. The accuracy and precision 
(%CV) observed for the calibration curve standards ranged from 
92.0 to 98.6 % and 1.18 to 6.17 % respectively. The LLOQ sample 
of 0.050ng/mL sirolimus concentration was measured with an 
acceptable accuracy and precision at a signal-to-noise ratio (S/N) 
of ≥ 70.  
 
 
Figure 3 UPLC-MS/MS chromatograms of blank blood during 
post-column infusion of (A) sirolimus and (B) tacrolimus (IS) 
 
 
 
Figure 4 MRM ion-chromatograms for carry over test of 
sirolimus (m/z 821.5 → 768.3) and tacrolimus (IS, m/z 931.6 → 
864.4) in (A) double blank blood (without analyte and IS), (B) 
sirolimus at ULOQ and IS (C) double blank blood (without 
analyte and IS) and (D) sirolimus at LLOQ and IS. 
 
The intra-batch precision (%CV) ranged from 1.27 to 4.05 
% and the accuracy was within 95.8 to 102.8 %.  For the 
inter-batch experiments, the precision varied from 3.38 to 5.44 % 
and the accuracy was within 98 to 102 % (Table 1).  
 
 
 
 
 
Table 1 Intra-batch and inter-batch precision and accuracy for sirolimus in human whole blood 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QC level Intra-batch (n = 6; single batch) Inter-batch (n = 30; 6 from each batch) 
Nominal 
concentration 
(ng/mL) 
Mean conc. 
found (ng/mL) 
CV (%) Accuracy (%) Mean conc. 
found for 5 
batches (ng/mL) 
CV (%) Accuracy (%) 
HQC (45.0) 43.1 1.27 95.8 44.1 4.48 97.9 
MQC-1 (25.0) 25.1 1.36 99.3 24.5 5.26 97.3 
MQC-2 (2.50) 2.57 3.77 102.8 2.53 5.44 101.4 
LQC (0.150) 0.148 4.05 98.7 0.148 3.38 98.7 
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Table 2 Absolute matrix effect and recovery of sirolimus from human whole blood (n = 6) 
 
A: Reconstitution solution; B: Spiked in extracted sample; C: Spiked before extraction;  
     CV: coefficient of variation; * [B/A × 100], values in parenthèses are for tacrolimus;  
     ** [C/B × 100], values in parenthèses are for tacrolimus 
Further, another essential criteria to evaluate matrix effect, expressed as relative matrix in different blood lots /batches showed % CV 
values in the measurement of slope of standard curves was 2.82 (Table 3).  
Table 3 Relative matrix effect in eight different lots of human blood 
Blood lot Slope of calibration 
curve 
Lot-1 0.03225 
Lot-2 0.03458 
Lot-3 0.03322 
Lot-4 0.03378 
Lot-5 0.03214 
Lot-6 0.03401 
Lot-7 0.03298 
Lot-8 0.03211 
Mean 0.03313 
Standard deviation 0.000935 
% Coefficient of variation 2.82 
 
Table 4 Stability of sirolimus under different conditions (n = 6) in human blood 
Storage condition Nomina
l conc.  
(ng/mL)  
Mean, stability  
samples + SD 
Change (%) * 
Bench top stability at room temperature; 9 h 
HQC 45.0 44.4 ± 3.22  -1.33 
LQC 0.150 0.147 ± 0.007 -2.01 
Wet extract stability at 5 °C; 50 h 
HQC 45.0 42.7 ± 0.97 -5.11 
LQC 0.150 0.155 ± 0.016  3.33 
Freeze & thaw stability; 5 cycles, -20°C 
HQC 45.0 43.4 ± 1.33  -3.56 
LQC 0.150 0.145 ± 0.002  -3.33 
Freeze & thaw stability; 5 Cycles, -70°C 
HQC 45.0 46.4 ± 1.83   3.11 
LQC 0.150 0.146 ± 0.003   2.67 
Long term matrix stability in matrix; 252 days, -20°C 
HQC 45.0 43.6 ± 0.65  -3.11 
LQC 0.150 0.145 ± 0.005 -3.33 
Long term matrix stability in matrix; 252 days, -70°C 
HQC 45.0 42.2 ± 1.40  -6.22 
 Mean area response 
 
Absolute  
matrix effect* 
Relative 
recovery** 
QC level A (CV, %) B (CV, %) C (CV, %)  
HQC 1880970 (3.7) 1852620 (3.0) 1772300 (2.4) 98.5 (95.6) 95.7 (93.6) 
MQC-1 1066071 (4.3) 1071812 (4.3) 990157 (3.6) 100.5 (97.2) 92.4 (96.2) 
MQC-2 102908 (3.4) 99747 (4.3) 93062 (3.3) 96.9 (94.3) 93.3 (91.7) 
LQC 6052 (1.5) 6116 (3.2) 5696 (3.0) 101.1 (97.5) 93.1 (94.4) 
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LQC 0.150 0.142 ± 0.002   5.33 
 
 
100
samples comparisonMean 
samples comparisonMean –  samplesstability Mean  (%)  Change* ×=
 
 
The stability results for sirolimus in human blood under different 
storage conditions are summarized in Table 4.  Stock solution 
samples kept for short-term stability remained unchanged up to 8 
h, while the long term stability under refrigerated temperature 
below 8°C, the solutions of sirolimus and IS were stable for a 
minimum of 40 days. Sirolimus samples in control human blood 
for bench top stability were stable for atleast 9h at 25°C and for 
minimum of five freeze and thaw cycles at –20 °C and –70 °C. 
Spiked blood samples stored at these two temperatures for long 
term stability were found stable for a minimum period of 252 
days. Autosampler stability (wet extract) of the spiked QC 
samples maintained at 5 °C was determined up to 50 h without 
significant drug loss. 
The dilution test was performed to validate method reliability for 
analyte concentration above the ULOQ concentration which may 
be encountered during subject sample analysis. The precision for 
dilution reliability of 1/2 and 1/10th dilution were 1.87 and 1.36 %, 
while the accuracy results were 98.01 and 95.90 % respectively. 
This is within the acceptance limit of 15% for precision (% CV) 
and 85 to 115% for accuracy. Method ruggedness was evaluated 
using re-injection of analyzed samples on two different columns 
of the same make and also with different analysts. The precision 
(% CV) and accuracy values for two different columns ranged 
from 3.66 to 7.03% and 95.3 to 106.1 % respectively at all four 
quality control levels.  For the experiment with different analysts, 
the results for precision and accuracy were within 2.78-5.10% and 
96.0 to 105.7 % respectively. 
Application to a pharmacokinetic/bioequivalence study 
To the best of our knowledge there are no reports on the 
pharmacokinetics of sirolimus in Indian subjects. Thus, the 
validated method was applied to quantify sirolimus concentration 
in human samples after oral administration of 2 mg oral dose of 
sirolimus. Figure 5 shows the blood concentration vs. time profile 
of sirolimus in 16 healthy subjects human. Around 1300 samples, 
including the calibration, QC and subject samples were analyzed 
during a period of 8 days and the precision and accuracy were well 
within the acceptable limits.  
 
Figure 5 Mean blood concentration-time profile of sirolimus after 
oral administration of 2 mg (test and reference) tablet formulation 
to 16 healthy subjects. 
The mean pharmacokinetic parameters for sirolimus 
(Table 5) and log transformed geometric least squares mean 
values for Cmax and AUC0-72 under fasting conditions are 
summarized in Table 6. The 90 % confidence interval of 
individual ratio geometric mean for test/reference was within 
89-108 %, which supports bioequivalence of the test formulation 
with the reference product in terms of rate and extent of 
absorption.  Furthermore, there was no adverse event during the 
course of the study. 
 
 
Table 5 Mean pharmacokinetic parameters following oral administration of 2 mg sirolimus in 16 healthy subjects 
 
Table 6 Comparison of treatment ratios and 90% CIs of natural log(Ln)-transformed parameters sirolimus 
 
Parameter 
Ratio 
(test/reference),% 
90% CI 
(Lower – Upper) 
Power 
Ln Cmax (ng/mL) 97.06 89.73 – 104.98 0.9971 
Ln AUC0-72h (h.ng/mL) 100.99 94.52 – 107.89 0.9995 
 
 
Incurred sample reanalysis (ISR) results are represented in Figure 
6. Out of 87 incurred samples studied, 55 samples showed % 
change for assay reproducibility within ± 5 %, 22 samples were 
within 5 to 10 %, 8 samples showed a change of  >10-15 %, while 
 
Parameter 
Mean ± standard deviation 
Test Reference 
Maximum blood concentration  
[Cmax (ng/mL)] 
10.594 ± 2.126 11.034 ± 2.583 
Time point of maximum plasma concentration [Tmax (h)] 4.437 ± 1.344 4.708 ± 1.088 
Area under the blood concentration-time curve [AUC 0 - 72h 
(h.ng/ml)] 
192.383 ± 39.392 193.715 ± 52.713 
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the remaining 2 samples were between >15 to 20 %. This 
authenticates the reproducibility of the proposed method. 
 
Figure 6 Incurred sample reanalysis results for sirolimus 
CONCLUSIONS 
The developed UPLC-MS/MS method for the quantitation of 
sirolimus in human blood was fully validated as per USFDA 
guidelines and can be efficiently used for therapeutic drug 
analysis. Despite the fact that there are several methods for the 
quantitation of sirolimus in whole blood, the present method 
offers significant advantages over those previously reported, in 
terms of sensitivity, reproducibility and overall analysis time. The 
chromatographic run time of 1.5 min per sample make it an 
attractive procedure in high-throughput bioanalysis of sirolimus.  
With dilution integrity up to 10-folds, it is possible to extend the 
upper limit of quantification to 90ng/mL.  In addition, the method 
is practically free from matrix interference as evident from the 
results obtained for absolute and relative matrix effect and post 
column infusion study. Furthermore, the reproducibility is 
realistically proved through incurred sample reanalysis.   
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